Abstract
| - Glycogen synthase kinase (GSK-3β) plays a crucialrole in Alzheimer's disease (AD). Its inhibition is a validapproach to the treatment of AD. In this initial letter, somethienyl and phenyl α-halomethyl ketones are described as newnon-ATP competitive inhibitors of GSK-3β. They are considered as lead compounds for designing and synthesizing newseries, to carry out SAR studies, clear up the mechanism ofaction, and, in general, evaluate their therapheutical usefulness.
|